Network Pharmacology-Based Investigation of the Therapeutic Mechanisms of Action of Danning Tablets in Nonalcoholic Fatty Liver Disease

Figure 5

Molecular docking models of the key target proteins with the key bioactive compounds. (a) IL6-quercetin, (b) MAPK8-stigmasterol, (c) VEGFA-quercetin, (d) CSP3-luteolin, (e) MYC- supraene, (f) APP-stigmasterol, (g) ALB-stigmasterol, (h) PPARG-luteolin, and (i) RELA-quercetin. The original ligands are labeled in green color, and the predicted poses of the bioactive compounds are labeled in pink color.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)